http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-111763-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b70512b2076a2759fccaecf9fe962d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2018-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-111763-A2 |
| titleOfInvention | PIRROLO-PYRIMIDINE COMPOUNDS AND THEIR USES |
| abstract | The compounds disclosed are related to treatments and therapies for disorders associated with protein kinase. There is also a need for compounds useful in the treatment or prevention or reduction of one or more symptoms of cancer, transplant rejection, and autoimmune diseases. Additionally, there is a need for methods to modulate the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. Claim 1: A compound of the formula (1), or a pharmaceutically acceptable salt, wherein: X is CR⁹ or N; R¹ is alkyl of 1 to 8 carbon atoms, CN, C (O) OR⁴ or CONR⁵R⁶, a 5-14 membered heteroaryl group, or a 3-14 membered cycloheteroalkyl group; R² is alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 14 carbon atoms, or a heteroaryl group of 5 to 14 members, and where R² can be substituted with one or more of alkyl of 1 to 8 carbon atoms , or OH; L is a bond, alkylene of 1 to 8 carbon atoms, C (O), or C (O) NR¹⁰, and wherein L may be substituted or unsubstituted; Y is H, R¹¹, NR¹²R¹³, OH, or Y is part of the group of formula (2), where Y is CR⁹ or N; wherein 0 to 3 R⁸ may be present, and R⁸ is alkyl of 1 to 8 carbon atoms, oxo, halogen, or two or more R⁸ may form a bridged alkyl group; W is CR⁹ or N; R³ is H, alkyl of 1 to 8 carbon atoms, alkyl of 1 to 8 carbon atoms-R¹⁴, cycloalkyl of 3 to 14 carbon atoms, C (O) -alkyl of 1 to 8 carbon atoms, halo-alkyl from 1 to 8 carbon atoms, alkyl of 1 to 8 carbon atoms-OH, C (O) NR¹⁴R¹⁵, cyano-alkyl of 1 to 8 carbon atoms, C (O) R¹⁴, alkyl of 0 to 8 carbon atoms -C (O) -alkyl of 0 to 8 carbon atoms-NR¹⁴R¹⁵, alkyl of 0 to 8 carbon atoms-C (O) OR¹⁴, NR¹⁴R¹⁵, SO₂-alkyl of 1 to 8 carbon atoms, alkyl of 1 to 8 carbon atoms-cycloalkyl of 3 to 14 carbon atoms, C (O) -alkyl of 1 to 8 carbon atoms-cycloalkyl of 3 to 14 carbon atoms, alkoxy of 1 to 8 carbon atoms, or OH, which it may be substituted or unsubstituted when R³ is not H; R⁹ is H or halogen; R⁴, R⁵, R⁶, R⁷, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵ are each independently selected from H, alkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 14 carbon atoms, a group 3 to 14 membered cyclo-heteroalkyl, an aryl group of 6 to 14 carbon atoms, a 5 to 14 membered heteroaryl group, alkoxy, C (O) H, C (N) OH, C (N) OCH₃, C (O) -alkyl of 1 to 3 carbon atoms, alkyl of 1 to 8 carbon atoms-NH₂, alkyl of 1 to 6 carbon atoms-OH, and wherein R⁴, R⁵, R⁶, R⁷, R¹⁰, R¹¹, R¹², and R¹³, R¹⁴, and R¹⁵ when they are not H, may be substituted or unsubstituted; m and n are independently from 0 to 2; and wherein L, R³, R⁴, R⁵, R⁶, R⁷, R¹⁰, R¹¹, R¹², and R¹³, R¹⁴, and R¹⁵ may be substituted with one or more alkyl of 1 to 8 carbon atoms, alkenyl of 2 to 8 carbon atoms, alkynyl of 2 to 8 carbon atoms, cycloalkyl of 3 to 14 carbon atoms, heteroaryl group of 5 to 14 members, aryl group of 6 to 14 carbon atoms, a cyclo-heteroalkyl group of 3 to 14 members , OH, (O), CN, alkoxy, halogen, or NH₂. |
| priorityDate | 2008-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 192.